Imatge de la portada

Author Correction: Liquid biopsy epigenomic profiling for cancer subtyping

Guardat en:
Publicat a:Nature Medicine vol. 30, no. 3 (Mar 2024), p. 907
Autor principal: Baca, Sylvan C.
Altres autors: Seo, Ji-Heui, Davidsohn, Matthew P., Fortunato, Brad, Semaan, Karl, Sotudian, Shahabbedin, Lakshminarayanan, Gitanjali, Diossy, Miklos, Qiu, Xintao, El Zarif, Talal, Savignano, Hunter, Canniff, John, Madueke, Ikenna, Saliby, Renee Maria, Zhang, Ziwei, Li, Rong, Jiang, Yijia, Taing, Len, Awad, Mark, Chau, Cindy H., DeCaprio, James A., Figg, William D., Greten, Tim F., Hata, Aaron N., Hodi, F. Stephen, Hughes, Melissa E., Ligon, Keith L., Lin, Nancy, Ng, Kimmie, Oser, Matthew G., Meador, Catherine, Parsons, Heather A., Pomerantz, Mark M., Rajan, Arun, Ritz, Jerome, Thakuria, Manisha, Tolaney, Sara M., Wen, Patrick Y., Long, Henry, Berchuck, Jacob E., Szallasi, Zoltan, Choueiri, Toni K., Freedman, Matthew L.
Publicat:
Nature Publishing Group
Accés en línia:Citation
Full Text - PDF
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

MARC

LEADER 00000nab a2200000uu 4500
001 2972995391
003 UK-CbPIL
022 |a 1078-8956 
022 |a 1546-170X 
024 7 |a 10.1038/s41591-023-02735-4  |2 doi 
035 |a 2972995391 
045 2 |b d20240301  |b d20240331 
084 |a 68925  |2 nlm 
100 1 |a Baca, Sylvan C.  |u Dana-Farber Cancer Institute, Department of Medical Oncology, Boston, USA (GRID:grid.65499.37) (ISNI:0000 0001 2106 9910); Dana-Farber Cancer Institute, Center for Functional Cancer Epigenetics, Boston, USA (GRID:grid.65499.37) (ISNI:0000 0001 2106 9910); Eli and Edythe L. Broad Institute, Cambridge, USA (GRID:grid.66859.34) (ISNI:0000 0004 0546 1623) 
245 1 |a Author Correction: Liquid biopsy epigenomic profiling for cancer subtyping 
260 |b Nature Publishing Group  |c Mar 2024 
513 |a Corrections/Retraction 
700 1 |a Seo, Ji-Heui  |u Dana-Farber Cancer Institute, Department of Medical Oncology, Boston, USA (GRID:grid.65499.37) (ISNI:0000 0001 2106 9910); Dana-Farber Cancer Institute, Center for Functional Cancer Epigenetics, Boston, USA (GRID:grid.65499.37) (ISNI:0000 0001 2106 9910) 
700 1 |a Davidsohn, Matthew P.  |u Dana-Farber Cancer Institute, Department of Medical Oncology, Boston, USA (GRID:grid.65499.37) (ISNI:0000 0001 2106 9910); Dana-Farber Cancer Institute, Center for Functional Cancer Epigenetics, Boston, USA (GRID:grid.65499.37) (ISNI:0000 0001 2106 9910) 
700 1 |a Fortunato, Brad  |u Dana-Farber Cancer Institute, Department of Medical Oncology, Boston, USA (GRID:grid.65499.37) (ISNI:0000 0001 2106 9910); Dana-Farber Cancer Institute, Center for Functional Cancer Epigenetics, Boston, USA (GRID:grid.65499.37) (ISNI:0000 0001 2106 9910); Eli and Edythe L. Broad Institute, Cambridge, USA (GRID:grid.66859.34) (ISNI:0000 0004 0546 1623) 
700 1 |a Semaan, Karl  |u Dana-Farber Cancer Institute, Department of Medical Oncology, Boston, USA (GRID:grid.65499.37) (ISNI:0000 0001 2106 9910); Eli and Edythe L. Broad Institute, Cambridge, USA (GRID:grid.66859.34) (ISNI:0000 0004 0546 1623) 
700 1 |a Sotudian, Shahabbedin  |u Dana-Farber Cancer Institute, Department of Medical Oncology, Boston, USA (GRID:grid.65499.37) (ISNI:0000 0001 2106 9910); Dana-Farber Cancer Institute, Center for Functional Cancer Epigenetics, Boston, USA (GRID:grid.65499.37) (ISNI:0000 0001 2106 9910); Eli and Edythe L. Broad Institute, Cambridge, USA (GRID:grid.66859.34) (ISNI:0000 0004 0546 1623) 
700 1 |a Lakshminarayanan, Gitanjali  |u Dana-Farber Cancer Institute, Department of Medical Oncology, Boston, USA (GRID:grid.65499.37) (ISNI:0000 0001 2106 9910); Dana-Farber Cancer Institute, Center for Functional Cancer Epigenetics, Boston, USA (GRID:grid.65499.37) (ISNI:0000 0001 2106 9910) 
700 1 |a Diossy, Miklos  |u Boston Children’s Hospital, Computational Health Informatics Program, Boston, USA (GRID:grid.2515.3) (ISNI:0000 0004 0378 8438) 
700 1 |a Qiu, Xintao  |u Dana-Farber Cancer Institute, Department of Medical Oncology, Boston, USA (GRID:grid.65499.37) (ISNI:0000 0001 2106 9910); Dana-Farber Cancer Institute, Center for Functional Cancer Epigenetics, Boston, USA (GRID:grid.65499.37) (ISNI:0000 0001 2106 9910) 
700 1 |a El Zarif, Talal  |u Dana-Farber Cancer Institute, Department of Medical Oncology, Boston, USA (GRID:grid.65499.37) (ISNI:0000 0001 2106 9910); Dana-Farber Cancer Institute, Center for Functional Cancer Epigenetics, Boston, USA (GRID:grid.65499.37) (ISNI:0000 0001 2106 9910) 
700 1 |a Savignano, Hunter  |u Dana-Farber Cancer Institute, Department of Medical Oncology, Boston, USA (GRID:grid.65499.37) (ISNI:0000 0001 2106 9910); Dana-Farber Cancer Institute, Center for Functional Cancer Epigenetics, Boston, USA (GRID:grid.65499.37) (ISNI:0000 0001 2106 9910) 
700 1 |a Canniff, John  |u Dana-Farber Cancer Institute, Department of Medical Oncology, Boston, USA (GRID:grid.65499.37) (ISNI:0000 0001 2106 9910); Dana-Farber Cancer Institute, Center for Functional Cancer Epigenetics, Boston, USA (GRID:grid.65499.37) (ISNI:0000 0001 2106 9910) 
700 1 |a Madueke, Ikenna  |u Dana-Farber Cancer Institute, Department of Medical Oncology, Boston, USA (GRID:grid.65499.37) (ISNI:0000 0001 2106 9910); Dana-Farber Cancer Institute, Center for Functional Cancer Epigenetics, Boston, USA (GRID:grid.65499.37) (ISNI:0000 0001 2106 9910) 
700 1 |a Saliby, Renee Maria  |u Dana-Farber Cancer Institute, Department of Medical Oncology, Boston, USA (GRID:grid.65499.37) (ISNI:0000 0001 2106 9910); Dana-Farber Cancer Institute, Center for Functional Cancer Epigenetics, Boston, USA (GRID:grid.65499.37) (ISNI:0000 0001 2106 9910) 
700 1 |a Zhang, Ziwei  |u Dana-Farber Cancer Institute, Department of Medical Oncology, Boston, USA (GRID:grid.65499.37) (ISNI:0000 0001 2106 9910); Dana-Farber Cancer Institute, Center for Functional Cancer Epigenetics, Boston, USA (GRID:grid.65499.37) (ISNI:0000 0001 2106 9910); Eli and Edythe L. Broad Institute, Cambridge, USA (GRID:grid.66859.34) (ISNI:0000 0004 0546 1623) 
700 1 |a Li, Rong  |u Dana-Farber Cancer Institute, Department of Medical Oncology, Boston, USA (GRID:grid.65499.37) (ISNI:0000 0001 2106 9910); Dana-Farber Cancer Institute, Center for Functional Cancer Epigenetics, Boston, USA (GRID:grid.65499.37) (ISNI:0000 0001 2106 9910) 
700 1 |a Jiang, Yijia  |u Dana-Farber Cancer Institute, Department of Medical Oncology, Boston, USA (GRID:grid.65499.37) (ISNI:0000 0001 2106 9910); Dana-Farber Cancer Institute, Center for Functional Cancer Epigenetics, Boston, USA (GRID:grid.65499.37) (ISNI:0000 0001 2106 9910) 
700 1 |a Taing, Len  |u Dana-Farber Cancer Institute, Department of Medical Oncology, Boston, USA (GRID:grid.65499.37) (ISNI:0000 0001 2106 9910); Dana-Farber Cancer Institute, Center for Functional Cancer Epigenetics, Boston, USA (GRID:grid.65499.37) (ISNI:0000 0001 2106 9910) 
700 1 |a Awad, Mark  |u Dana-Farber Cancer Institute, Harvard Medical School, Lowe Center for Thoracic Oncology, Boston, USA (GRID:grid.65499.37) (ISNI:0000 0001 2106 9910) 
700 1 |a Chau, Cindy H.  |u National Cancer Institute, National Institutes of Health, Molecular Pharmacology Section, Genitourinary Malignancies Branch, Center for Cancer Research, Bethesda, USA (GRID:grid.48336.3a) (ISNI:0000 0004 1936 8075) 
700 1 |a DeCaprio, James A.  |u Dana-Farber Cancer Institute, Department of Medical Oncology, Boston, USA (GRID:grid.65499.37) (ISNI:0000 0001 2106 9910); Brigham and Women’s Hospital, Harvard Medical School, Department of Medicine, Boston, USA (GRID:grid.38142.3c) (ISNI:000000041936754X) 
700 1 |a Figg, William D.  |u National Cancer Institute, National Institutes of Health, Molecular Pharmacology Section, Genitourinary Malignancies Branch, Center for Cancer Research, Bethesda, USA (GRID:grid.48336.3a) (ISNI:0000 0004 1936 8075) 
700 1 |a Greten, Tim F.  |u National Cancer Institute, National Institutes of Health, Liver Cancer Program, Center for Cancer Research, Bethesda, USA (GRID:grid.48336.3a) (ISNI:0000 0004 1936 8075) 
700 1 |a Hata, Aaron N.  |u Massachusetts General Hospital Cancer Center, Boston, USA (GRID:grid.32224.35) (ISNI:0000 0004 0386 9924); Massachusetts General Hospital and Harvard Medical School, Department of Medicine, Boston, USA (GRID:grid.32224.35) (ISNI:0000 0004 0386 9924) 
700 1 |a Hodi, F. Stephen  |u Dana-Farber Cancer Institute, Department of Medical Oncology, Boston, USA (GRID:grid.65499.37) (ISNI:0000 0001 2106 9910) 
700 1 |a Hughes, Melissa E.  |u Dana-Farber Cancer Institute, Department of Medical Oncology, Boston, USA (GRID:grid.65499.37) (ISNI:0000 0001 2106 9910) 
700 1 |a Ligon, Keith L.  |u Dana-Farber Cancer Institute, Department of Medical Oncology, Boston, USA (GRID:grid.65499.37) (ISNI:0000 0001 2106 9910); Dana-Farber Cancer Institute, Department of Pathology, Boston, USA (GRID:grid.65499.37) (ISNI:0000 0001 2106 9910) 
700 1 |a Lin, Nancy  |u Dana-Farber Cancer Institute, Department of Medical Oncology, Boston, USA (GRID:grid.65499.37) (ISNI:0000 0001 2106 9910) 
700 1 |a Ng, Kimmie  |u Dana-Farber Cancer Institute, Department of Medical Oncology, Boston, USA (GRID:grid.65499.37) (ISNI:0000 0001 2106 9910) 
700 1 |a Oser, Matthew G.  |u Dana-Farber Cancer Institute, Department of Medical Oncology, Boston, USA (GRID:grid.65499.37) (ISNI:0000 0001 2106 9910) 
700 1 |a Meador, Catherine  |u Massachusetts General Hospital Cancer Center, Boston, USA (GRID:grid.32224.35) (ISNI:0000 0004 0386 9924); Massachusetts General Hospital and Harvard Medical School, Department of Medicine, Boston, USA (GRID:grid.32224.35) (ISNI:0000 0004 0386 9924) 
700 1 |a Parsons, Heather A.  |u Dana-Farber Cancer Institute, Department of Medical Oncology, Boston, USA (GRID:grid.65499.37) (ISNI:0000 0001 2106 9910) 
700 1 |a Pomerantz, Mark M.  |u Dana-Farber Cancer Institute, Department of Medical Oncology, Boston, USA (GRID:grid.65499.37) (ISNI:0000 0001 2106 9910); Dana-Farber Cancer Institute, Center for Functional Cancer Epigenetics, Boston, USA (GRID:grid.65499.37) (ISNI:0000 0001 2106 9910) 
700 1 |a Rajan, Arun  |u National Cancer Institute, National Institute of Health, Thoracic and Gastrointestinal Malignancies Branch, Center for Cancer Research, Bethesda, USA (GRID:grid.48336.3a) (ISNI:0000 0004 1936 8075) 
700 1 |a Ritz, Jerome  |u Dana-Farber Cancer Institute, Department of Medical Oncology, Boston, USA (GRID:grid.65499.37) (ISNI:0000 0001 2106 9910) 
700 1 |a Thakuria, Manisha  |u Brigham and Women’s Hospital, Harvard Medical School, Department of Dermatology, Boston, USA (GRID:grid.38142.3c) (ISNI:000000041936754X); Dana-Farber/Brigham and Women’s Cancer Center, Center for Cutaneous Oncology, Boston, USA (GRID:grid.417747.6) (ISNI:0000 0004 0460 3896) 
700 1 |a Tolaney, Sara M.  |u Dana-Farber Cancer Institute, Department of Medical Oncology, Boston, USA (GRID:grid.65499.37) (ISNI:0000 0001 2106 9910) 
700 1 |a Wen, Patrick Y.  |u Dana-Farber Cancer Institute, Center for Neuro-Oncology, Boston, USA (GRID:grid.65499.37) (ISNI:0000 0001 2106 9910); Brigham and Women’s Hospital and Harvard Medical School, Department of Neurology, Boston, USA (GRID:grid.62560.37) (ISNI:0000 0004 0378 8294) 
700 1 |a Long, Henry  |u Dana-Farber Cancer Institute, Department of Medical Oncology, Boston, USA (GRID:grid.65499.37) (ISNI:0000 0001 2106 9910); Dana-Farber Cancer Institute, Center for Functional Cancer Epigenetics, Boston, USA (GRID:grid.65499.37) (ISNI:0000 0001 2106 9910) 
700 1 |a Berchuck, Jacob E.  |u Dana-Farber Cancer Institute, Department of Medical Oncology, Boston, USA (GRID:grid.65499.37) (ISNI:0000 0001 2106 9910); Dana-Farber Cancer Institute, Center for Functional Cancer Epigenetics, Boston, USA (GRID:grid.65499.37) (ISNI:0000 0001 2106 9910) 
700 1 |a Szallasi, Zoltan  |u Boston Children’s Hospital, Computational Health Informatics Program, Boston, USA (GRID:grid.2515.3) (ISNI:0000 0004 0378 8438); Danish Cancer Institute, Copenhagen, Denmark (GRID:grid.2515.3); Semmelweis University, Department of Bioinformatics and Department of Pathology, Forensic and Insurance Medicine, Budapest, Hungary (GRID:grid.11804.3c) (ISNI:0000 0001 0942 9821) 
700 1 |a Choueiri, Toni K.  |u Dana-Farber Cancer Institute, Department of Medical Oncology, Boston, USA (GRID:grid.65499.37) (ISNI:0000 0001 2106 9910) 
700 1 |a Freedman, Matthew L.  |u Dana-Farber Cancer Institute, Department of Medical Oncology, Boston, USA (GRID:grid.65499.37) (ISNI:0000 0001 2106 9910); Dana-Farber Cancer Institute, Center for Functional Cancer Epigenetics, Boston, USA (GRID:grid.65499.37) (ISNI:0000 0001 2106 9910); Eli and Edythe L. Broad Institute, Cambridge, USA (GRID:grid.66859.34) (ISNI:0000 0004 0546 1623) 
773 0 |t Nature Medicine  |g vol. 30, no. 3 (Mar 2024), p. 907 
786 0 |d ProQuest  |t Science Database 
856 4 1 |3 Citation  |u https://www.proquest.com/docview/2972995391/citation/embedded/75I98GEZK8WCJMPQ?source=fedsrch 
856 4 0 |3 Full Text - PDF  |u https://www.proquest.com/docview/2972995391/fulltextPDF/embedded/75I98GEZK8WCJMPQ?source=fedsrch